1817 related articles for article (PubMed ID: 26716830)
41. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
42. Total costs of treating venous thromboembolism: implication of different cost perspectives in a Danish setting.
Nielsen A; Poulsen PB; Dybro L; Kloster B; Lorentzen A; Olsen J; Kümler T
J Med Econ; 2019 Dec; 22(12):1321-1327. PubMed ID: 31516054
[No Abstract] [Full Text] [Related]
43. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis.
Robertson L; Kesteven P; McCaslin JE
Cochrane Database Syst Rev; 2015 Jun; (6):CD010956. PubMed ID: 26123214
[TBL] [Abstract][Full Text] [Related]
44. Meta-analysis on efficacy and safety of new oral anticoagulants for venous thromboembolism prophylaxis in elderly elective postarthroplasty patients.
Pathak R; Giri S; Karmacharya P; Aryal MR; Poudel DR; Ghimire S; Jehangir A; Shaikh B; Rettew A; Donato AA
Blood Coagul Fibrinolysis; 2015 Dec; 26(8):934-9. PubMed ID: 26258674
[TBL] [Abstract][Full Text] [Related]
45. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Graff J; Harder S
Clin Pharmacokinet; 2013 Apr; 52(4):243-54. PubMed ID: 23389892
[TBL] [Abstract][Full Text] [Related]
46. Re: 'Re. Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of VTE: A Systematic Review and Meta-analysis of Phase III Trials'.
Kakkos SK; Kirkilesis GI; Tsolakis IA
Eur J Vasc Endovasc Surg; 2015 Jul; 50(1):127. PubMed ID: 25882231
[No Abstract] [Full Text] [Related]
47. Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer.
Verso M; Agnelli G; Prandoni P
Intern Emerg Med; 2015 Sep; 10(6):651-6. PubMed ID: 25840679
[TBL] [Abstract][Full Text] [Related]
48. Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far?
Voigtlaender M; Langer F
Hamostaseologie; 2017 Oct; 37(4):241-255. PubMed ID: 28508916
[TBL] [Abstract][Full Text] [Related]
49. Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta-Analysis.
Tereshchenko LG; Henrikson CA; Cigarroa J; Steinberg JS
J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27207998
[TBL] [Abstract][Full Text] [Related]
50. Clinical experience with the new oral anticoagulants for treatment of venous thromboembolism.
Bacchus F; Schulman S
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):513-9. PubMed ID: 25717178
[TBL] [Abstract][Full Text] [Related]
51. Antidotes to non-vitamin K oral anticoagulants: necessary or not?
Proietti M; Lip GY
Expert Opin Pharmacother; 2015; 16(11):1573-6. PubMed ID: 26077323
[TBL] [Abstract][Full Text] [Related]
52. Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: New Insights from Randomized Controlled Trials.
Rojas-Hernandez CM; Oo TH
Drugs; 2019 Apr; 79(6):621-631. PubMed ID: 30905033
[TBL] [Abstract][Full Text] [Related]
53. The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: A network meta-analysis.
Oh HJ; Ryu KH; Park BJ; Yoon BH
Medicine (Baltimore); 2021 Mar; 100(11):e25216. PubMed ID: 33726018
[TBL] [Abstract][Full Text] [Related]
54. Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies.
Deitelzweig S; Farmer C; Luo X; Vo L; Li X; Hamilton M; Horblyuk R; Ashaye A
Curr Med Res Opin; 2017 Sep; 33(9):1583-1594. PubMed ID: 28644048
[TBL] [Abstract][Full Text] [Related]
55. [Not Available].
Själander S; Själander A
Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512136
[No Abstract] [Full Text] [Related]
56. Comparative Clinical Outcomes of Edoxaban in Adults With Nonvalvular Atrial Fibrillation.
Aronow WS; Shamliyan TA
Am J Ther; 2020; 27(3):e270-e285. PubMed ID: 30277905
[TBL] [Abstract][Full Text] [Related]
57. Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease.
Voukalis C; Lip GY; Shantsila E
Expert Opin Pharmacother; 2016 Oct; 17(15):2033-47. PubMed ID: 27667112
[TBL] [Abstract][Full Text] [Related]
58. All-Cause Mortality Risk with Direct Oral Anticoagulants and Warfarin in the Primary Treatment of Venous Thromboembolism.
Roetker NS; Lutsey PL; Zakai NA; Alonso A; Adam TJ; MacLehose RF
Thromb Haemost; 2018 Sep; 118(9):1637-1645. PubMed ID: 30103250
[TBL] [Abstract][Full Text] [Related]
59. Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: A meta-analysis of interventional trials.
Loffredo L; Perri L; Violi F
Dig Liver Dis; 2015 May; 47(5):429-31. PubMed ID: 25732432
[TBL] [Abstract][Full Text] [Related]
60. Non-vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights.
Kumana CR; Cheung BM; Siu DC; Tse HF; Lauder IJ
Cardiovasc Ther; 2016 Apr; 34(2):100-6. PubMed ID: 26727005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
